Cargando…

The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia

Notwithstanding the introduction of Tyrosine Kinase Inhibitors (TKIs) revolutionized the outcome of Chronic Myeloid Leukemia (CML), one third of patients still suspends treatment for failure response. Recent research demonstrated that several BCR/ABL1-independent mechanisms can sustain resistance, b...

Descripción completa

Detalles Bibliográficos
Autores principales: Grassi, Susanna, Palumbo, Sara, Mariotti, Veronica, Liberati, Diego, Guerrini, Francesca, Ciabatti, Elena, Salehzadeh, Serena, Baratè, Claudia, Balducci, Serena, Ricci, Federica, Buda, Gabriele, Iovino, Lorenzo, Mazziotta, Francesco, Ghio, Francesco, Ercolano, Giacomo, Di Paolo, Antonello, Cecchettini, Antonella, Baldini, Chiara, Mattii, Letizia, Pellegrini, Silvia, Petrini, Mario, Galimberti, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601352/
https://www.ncbi.nlm.nih.gov/pubmed/31293972
http://dx.doi.org/10.3389/fonc.2019.00532
_version_ 1783431283205996544
author Grassi, Susanna
Palumbo, Sara
Mariotti, Veronica
Liberati, Diego
Guerrini, Francesca
Ciabatti, Elena
Salehzadeh, Serena
Baratè, Claudia
Balducci, Serena
Ricci, Federica
Buda, Gabriele
Iovino, Lorenzo
Mazziotta, Francesco
Ghio, Francesco
Ercolano, Giacomo
Di Paolo, Antonello
Cecchettini, Antonella
Baldini, Chiara
Mattii, Letizia
Pellegrini, Silvia
Petrini, Mario
Galimberti, Sara
author_facet Grassi, Susanna
Palumbo, Sara
Mariotti, Veronica
Liberati, Diego
Guerrini, Francesca
Ciabatti, Elena
Salehzadeh, Serena
Baratè, Claudia
Balducci, Serena
Ricci, Federica
Buda, Gabriele
Iovino, Lorenzo
Mazziotta, Francesco
Ghio, Francesco
Ercolano, Giacomo
Di Paolo, Antonello
Cecchettini, Antonella
Baldini, Chiara
Mattii, Letizia
Pellegrini, Silvia
Petrini, Mario
Galimberti, Sara
author_sort Grassi, Susanna
collection PubMed
description Notwithstanding the introduction of Tyrosine Kinase Inhibitors (TKIs) revolutionized the outcome of Chronic Myeloid Leukemia (CML), one third of patients still suspends treatment for failure response. Recent research demonstrated that several BCR/ABL1-independent mechanisms can sustain resistance, but the relationship between these mechanisms and the outcome has not yet been fully understood. This study was designed to evaluate in a “real-life” setting if a change of expression of several genes involved in the WNT/BETA-CATENIN, JAK-STAT, and POLYCOMB pathways might condition the outcome of CML patients receiving TKIs. Thus, the expression of 255 genes, related to the aforementioned pathways, was measured by quantitative PCR after 6 months of therapy and compared with levels observed at diagnosis in 11 CML patients, in order to find possible correlations with quality of response to treatment and event-free-survival (EFS). These results were then re-analyzed by the principal component method (PCA) for tempting to better cluster resistant cases. After 12 months of therapy, 6 patients achieved an optimal response and 5 were “resistant;” after application of both statistical methods, it was evident that in all pathways a significant overall up-regulation occurred, and that WNT was the pathway mostly responsible for the TKIs resistance. Indeed, 100% of patients with a “low” up-regulation of this pathway achieved an optimal response vs. 33% of those who showed a “high” gene over-expression (p = 0.016). Analogously, the 24-months EFS resulted significantly influenced by the degree of up-regulation of the WNT signaling: all patients with a “low” up-regulation were event-free vs. 33% of those who presented a “high” gene expression (p = 0.05). In particular, the PCA analysis confirmed the role of WNT pathway and showed that the most significantly up-regulated genes with negative prognostic value were DKK, WNT6, WISP1, and FZD8. In conclusion, our results sustain the need of a wide and multitasking approach in order to understand the resistance mechanisms in CML.
format Online
Article
Text
id pubmed-6601352
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-66013522019-07-10 The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia Grassi, Susanna Palumbo, Sara Mariotti, Veronica Liberati, Diego Guerrini, Francesca Ciabatti, Elena Salehzadeh, Serena Baratè, Claudia Balducci, Serena Ricci, Federica Buda, Gabriele Iovino, Lorenzo Mazziotta, Francesco Ghio, Francesco Ercolano, Giacomo Di Paolo, Antonello Cecchettini, Antonella Baldini, Chiara Mattii, Letizia Pellegrini, Silvia Petrini, Mario Galimberti, Sara Front Oncol Oncology Notwithstanding the introduction of Tyrosine Kinase Inhibitors (TKIs) revolutionized the outcome of Chronic Myeloid Leukemia (CML), one third of patients still suspends treatment for failure response. Recent research demonstrated that several BCR/ABL1-independent mechanisms can sustain resistance, but the relationship between these mechanisms and the outcome has not yet been fully understood. This study was designed to evaluate in a “real-life” setting if a change of expression of several genes involved in the WNT/BETA-CATENIN, JAK-STAT, and POLYCOMB pathways might condition the outcome of CML patients receiving TKIs. Thus, the expression of 255 genes, related to the aforementioned pathways, was measured by quantitative PCR after 6 months of therapy and compared with levels observed at diagnosis in 11 CML patients, in order to find possible correlations with quality of response to treatment and event-free-survival (EFS). These results were then re-analyzed by the principal component method (PCA) for tempting to better cluster resistant cases. After 12 months of therapy, 6 patients achieved an optimal response and 5 were “resistant;” after application of both statistical methods, it was evident that in all pathways a significant overall up-regulation occurred, and that WNT was the pathway mostly responsible for the TKIs resistance. Indeed, 100% of patients with a “low” up-regulation of this pathway achieved an optimal response vs. 33% of those who showed a “high” gene over-expression (p = 0.016). Analogously, the 24-months EFS resulted significantly influenced by the degree of up-regulation of the WNT signaling: all patients with a “low” up-regulation were event-free vs. 33% of those who presented a “high” gene expression (p = 0.05). In particular, the PCA analysis confirmed the role of WNT pathway and showed that the most significantly up-regulated genes with negative prognostic value were DKK, WNT6, WISP1, and FZD8. In conclusion, our results sustain the need of a wide and multitasking approach in order to understand the resistance mechanisms in CML. Frontiers Media S.A. 2019-06-24 /pmc/articles/PMC6601352/ /pubmed/31293972 http://dx.doi.org/10.3389/fonc.2019.00532 Text en Copyright © 2019 Grassi, Palumbo, Mariotti, Liberati, Guerrini, Ciabatti, Salehzadeh, Baratè, Balducci, Ricci, Buda, Iovino, Mazziotta, Ghio, Ercolano, Di Paolo, Cecchettini, Baldini, Mattii, Pellegrini, Petrini and Galimberti. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Grassi, Susanna
Palumbo, Sara
Mariotti, Veronica
Liberati, Diego
Guerrini, Francesca
Ciabatti, Elena
Salehzadeh, Serena
Baratè, Claudia
Balducci, Serena
Ricci, Federica
Buda, Gabriele
Iovino, Lorenzo
Mazziotta, Francesco
Ghio, Francesco
Ercolano, Giacomo
Di Paolo, Antonello
Cecchettini, Antonella
Baldini, Chiara
Mattii, Letizia
Pellegrini, Silvia
Petrini, Mario
Galimberti, Sara
The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia
title The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia
title_full The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia
title_fullStr The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia
title_full_unstemmed The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia
title_short The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia
title_sort wnt pathway is relevant for the bcr-abl1-independent resistance in chronic myeloid leukemia
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601352/
https://www.ncbi.nlm.nih.gov/pubmed/31293972
http://dx.doi.org/10.3389/fonc.2019.00532
work_keys_str_mv AT grassisusanna thewntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT palumbosara thewntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT mariottiveronica thewntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT liberatidiego thewntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT guerrinifrancesca thewntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT ciabattielena thewntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT salehzadehserena thewntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT barateclaudia thewntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT balducciserena thewntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT riccifederica thewntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT budagabriele thewntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT iovinolorenzo thewntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT mazziottafrancesco thewntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT ghiofrancesco thewntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT ercolanogiacomo thewntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT dipaoloantonello thewntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT cecchettiniantonella thewntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT baldinichiara thewntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT mattiiletizia thewntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT pellegrinisilvia thewntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT petrinimario thewntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT galimbertisara thewntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT grassisusanna wntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT palumbosara wntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT mariottiveronica wntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT liberatidiego wntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT guerrinifrancesca wntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT ciabattielena wntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT salehzadehserena wntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT barateclaudia wntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT balducciserena wntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT riccifederica wntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT budagabriele wntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT iovinolorenzo wntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT mazziottafrancesco wntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT ghiofrancesco wntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT ercolanogiacomo wntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT dipaoloantonello wntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT cecchettiniantonella wntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT baldinichiara wntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT mattiiletizia wntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT pellegrinisilvia wntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT petrinimario wntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia
AT galimbertisara wntpathwayisrelevantforthebcrabl1independentresistanceinchronicmyeloidleukemia